All In Biotech

Drug Trial Radar · NCT05104892

Proof of Concept Study of Rilzabrutinib in Adult Participants With Moderate-to-severe Asthma

A Randomized, Double-blind, Placebo-controlled, Parallel-group, 12 Week Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety, and Tolerability of Rilzabrutinib in Participants With Moderate-to-severe Asthma Who Are Not Well Controlled on Inhaled Corticosteroid (ICS) Plus Long-acting β2 Adrenergic Agonist (LABA) Therapy

Last checked: Nov 20, 2026Latest source record: Mar 7, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 196 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

196

Actual

Start

Dec 12, 2021

Primary completion

Feb 6, 2024

Study completion Feb 28, 2024

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Nov 3, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a parallel, treatment, Phase 2, double-blind, 2 arm, 12-week Proof of Concept (PoC) study with 2 staggered cohorts (2 arms in each cohort) that is designed to assess the efficacy, safety, and tolerability of rilzabrutinib in adult participants (aged 18-70 years) with moderate-to-severe asthma who are not well controlled on ICS/LABA therapy. Study treatment includes investigational medicinal product (IMP) (rilzabrutinib or placebo) added-on to a background therapy of ICS/LABA (fluticasone/salmeterol \[non-investigational medicinal product\], standardized at screening). Background therapy of ICS/LABA will be withdrawn during the 12week randomized treatment period and resumed at the end of the IMP treatment period, as outlined below: * Screening period (4 weeks) * Randomized IMP treatment period (12 weeks ± 3 days) * Background therapy stabilization phase (4 weeks) * Background therapy withdrawal phase (4-5 weeks) * No background therapy phase (3-4 weeks) * Post IMP treatment safety follow-up period (4 weeks ± 3 days)

Conditions

  • Asthma

Interventions

  • RilzabrutinibDrug

    Pharmaceutical form: Tablet Route of administration: Oral

  • placeboDrug

    Pharmaceutical form: Tablet Route of administration: Oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of participants with an LOAC event during the treatment periodTime frame: Until Week 12

Locations

51 sites in 13 countries. Site status is shown where the registry gives one.

  • Investigational Site Number : 0320001

    Buenos Aires, Argentina

  • Investigational Site Number : 0320005

    Ciudad Autonoma Buenos Aires, Argentina

  • Investigational Site Number : 0320002

    Ciudad Autonoma Buenos Aires, Argentina

  • Investigational Site Number : 0320004

    Berazategui, Buenos Aires, Argentina

  • Investigational Site Number : 0320006

    CABA, Buenos Aires, Argentina

  • Investigational Site Number : 0320003

    CABA, Buenos Aires, Argentina

  • Investigational Site Number : 1000004

    Kozloduy, Bulgaria

  • Investigational Site Number : 1000001

    Rousse, Bulgaria

  • Investigational Site Number : 1000003

    Sevlievo, Bulgaria

  • Investigational Site Number : 1000002

    Sofia, Bulgaria

  • Investigational Site Number : 1240006

    Vancouver, British Columbia, Canada

  • Investigational Site Number : 1240005

    Waterloo, Ontario, Canada

  • Investigational Site Number : 1520005

    Curicó, Maule Region, Chile

  • Investigational Site Number : 1520002

    Talca, Maule Region, Chile

  • Investigational Site Number : 1520007

    Santaigo, Reg Metropolitana de Santiago, Chile

  • Investigational Site Number : 1520001

    Santiago, Reg Metropolitana de Santiago, Chile

  • Investigational Site Number : 1520004

    Santiago, Reg Metropolitana de Santiago, Chile

  • Investigational Site Number : 1520003

    Santiago, Reg Metropolitana de Santiago, Chile

  • Investigational Site Number : 1520006

    Quillota, Valparaiso, Chile

  • Investigational Site Number : 6420001

    Düsseldorf, Germany

  • Investigational Site Number : 3480001

    Edelény, Hungary

  • Investigational Site Number : 3480004

    Hajdunánás, Hungary

  • Investigational Site Number : 3480003

    Pécs, Hungary

  • Investigational Site Number : 4840003

    Durango, Mexico

  • Investigational Site Number : 4840004

    Veracruz, Mexico

  • Investigational Site Number : 4840001

    Guadalajara, Jalisco, Mexico

  • Investigational Site Number : 4840002

    Monterrey, Nuevo León, Mexico

  • Investigational Site Number : 4840005

    San Juan del Río, Querétaro, Mexico

  • Investigational Site Number : 6160005

    Bialystok, Poland

  • Investigational Site Number : 6160002

    Krakow, Poland

  • Investigational Site Number : 6160010

    Lodz, Poland

  • Investigational Site Number : 6160001

    Lodz, Poland

  • Investigational Site Number : 6160009

    Poznan, Greater Poland Voivodeship, Poland

  • Investigational Site Number : 6160007

    Lublin, Lubusz Voivodeship, Poland

  • Investigational Site Number : 6160003

    Bialystok, Podlaskie Voivodeship, Poland

  • Investigational Site Number : 6160006

    Gdansk, Pomeranian Voivodeship, Poland

  • Investigational Site Number : 6160008

    Ostrowiec Świętokrzyski, Świętokrzyskie Voivodeship, Poland

  • Investigational Site Number : 6420002

    Cluj-Napoca, Romania

  • Investigational Site Number : 4100001

    Seoul, South Korea

  • Investigational Site Number : 4100007

    Daegu, Daegu, South Korea

Showing 40 of 51 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.